Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,914
datasets available to search
ShareScore release 0.9.0
Dataset results
2,914 results for “replacement”
Karyotype analysis of S. cerevisiae chromosome replacement lines - alpha-type cells
GEO Series GSE12776. Saccharomyces cerevisiae; Saccharomyces bayanus. 24 samples. Type: Genome variation profiling by genome tiling array.
Engineering transcriptional regulators using REPLACE
GEO Series GSE271879. Mesocricetus auratus. 3 samples. Type: Other.
Differential gene expression in APOE3 and APOE4 gene targeted replacement mice
GEO Series GSE42930. Mus musculus. 10 samples. Type: Expression profiling by array.
Dataset of Study Replacing Sucrose with Erythritol
<p>Dataset of Study "Replacing Sucrose with the Non-Nutritive Sweetener Erythritol does not alter Gut Peptide Release or Energy Intake in Lean and Obese People"</p> <p>Authors: Joost Overduin <sup>1</sup>, Tinh-Hai Collet <sup>2</sup>, Nenad Medic <sup>2,3</sup>, Elana Henning <sup>2</sup>, Julia M. Keogh <sup>2</sup>, Faye Forsyth <sup>2</sup>, Cheryl Stephenson <sup>2</sup>, Marja W. Kanning <sup>1</sup>, Rianne M.A.J. Ruijschop <sup>1</sup>, I. Sadaf Farooqi <sup>2</sup>, Agatha A. van der Klaauw <sup>2</sup>.</p> <p>Affiliations: <sup>1</sup> NIZO Food Research, Ede, The Netherlands; <sup>2</sup> University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, United Kingdom; <sup>3</sup> Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom.</p> <p>Submitted to PLOS One, Sept 2015, currently under peer-review</p>
Outcome of transcatheter aortic valve replacement in bicuspid aortic valve stenosis with new-generation devices.
<p>Dataset from Gorla R, Casenghi M, Finotello A, De Marco F, Morganti S, Regazzoli D, Bianchi G, Acerbi E, Popolo Rubbio A, Brambilla N, Testa L, Castriota F, Auricchio F, Reimers B, Bedogni F. Outcome of transcatheter aortic valve replacement in bicuspid aortic valve stenosis with new-generation devices. Interact Cardiovasc Thorac Surg. 2021 Jan 1;32(1):20-28. doi: 10.1093/icvts/ivaa231. PMID: 33201993.</p> <p>Abstract</p> <p><strong>Objectives: </strong>To compare device success and paravalvular leak rates of 3 new-generation transcatheter aortic valve replacement devices in patients with bicuspid aortic valve stenosis and to test their biomechanical performance in a computer-based simulation model of aortic root with increasing ellipticity.</p> <p><strong>Methods: </strong>This retrospective multicentre study included 56 bicuspid aortic valve patients undergoing transcatheter aortic valve replacement with new-generation devices: Lotus/Lotus Edge (N = 15; 27%), Evolut-R (N = 20; 36%) and ACURATE neo (N = 21; 37%). Three virtual simulation models of aortic root with increasing index of eccentricity (0-0.25-0.5) were implemented. Stress distribution, stent-root contact area and paravalvular orifice area were computed.</p> <p><strong>Results: </strong>Device success was achieved in 43/56 patients (77%) with comparable rates among Lotus (87%), Evolut-R (60%) and ACURATE neo (86%; P = 0.085). Moderate paravalvular leak rate was significantly lower in the Lotus group as compared to Evolut-R group (0% vs 30%; P = 0.027) and comparable to the ACURATE neo group (0% vs 10%; P = 0.33). By index of eccentricity = 0.5, Lotus showed a uniform and symmetric pattern of stress distribution with absent paravalvular orifice area, ACURATE neo showed a mild asymmetry with small paravalvular orifice area (1.1 mm2), whereas a severely asymmetric pattern was evident with Evolut-R, resulting in a large paravalvular orifice area (12.0 mm2).</p> <p><strong>Conclusions: </strong>Transcatheter aortic valve replacement in bicuspid aortic valve patients with new-generation devices showed comparable device success rates. Lotus showed moderate paravalvular leak rate comparable to that of ACURATE neo and significantly lower than Evolut-R. On simulation, Lotus and ACURATE neo showed optimal adaptability to elliptic anatomies as compared to Evolut-R.</p>
First-in-Man Study Evaluating the Emblok Embolic Protection System During Transcatheter Aortic Valve Replacement
<p>Dataset from the article Latib A, Mangieri A, Vezzulli P, Spagnolo P, Sardanelli F, Fellegara G, Pagnesi M, Giannini F, Falini A, Gorla R, Montorfano M, Bedogni F, Colombo A, Popma J, Merhi WM, De Marco F. First-in-Man Study Evaluating the Emblok Embolic Protection System During Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2020 Apr 13;13(7):860-868. doi: 10.1016/j.jcin.2019.11.017. PMID: 32273098.</p> <p><strong>Abstract</strong></p> <p><strong>Objectives: </strong>This study sought to evaluate the feasibility of complete cerebral protection during transcatheter aortic valve replacement (TAVR) with a novel embolic protection device.</p> <p><strong>Background: </strong>Evidences and data about new cerebral embolic protection devices are lacking and scarce.</p> <p><strong>Methods: </strong>A prospective, nonrandomized, multicenter, first-in-man pilot study designed to evaluate the efficacy and safety of cerebral embolic protection utilizing the Emblok embolic protection system (Innovative Cardiovascular Solutions, Grand Rapids, Michigan) during TAVR. The Emblok is a transfemoral aortic filter that provide full coverage of the epiaortic vessels. Brain diffusion-weighted magnetic resonance imaging (DW-MRI) was performed at baseline and 2 to 5 days after TAVR. Primary endpoints were technical success and immediate cerebral embolic burden after TAVR, defined as number and volume of new brain lesions detected with DW-MRI at days 2 to 5 post-TAVR compared with baseline.</p> <p><strong>Results: </strong>A total of 20 subjects were enrolled. The Emblok system was successfully positioned in all the cases. At 30-day follow-up, no major adverse cardiovascular and cerebrovascular events occurred. Nineteen (95%) patients had new ischemic defects at post-procedural DW-MRI. The median number of new lesions per patient was 10.00 (interquartile range [IQR]: 4.75 to 15.25). The total new lesion volume was 199.9 mm<sup>3</sup> (IQR: 83.9 to 447.5 mm<sup>3</sup>) and the mean lesion volume per lesion was 42.5 mm<sup>3</sup> (IQR: 21.5 to 75.6 mm<sup>3</sup>). Histopathologic analysis showed evidence of significant debris in 18 (90%) filters.</p> <p><strong>Conclusions: </strong>The Emblok embolic protection system appears to be feasible and safe during TAVR. The device was successfully placed and retrieved in all cases and no neurological events were observed. Cerebral total new lesion volume was similar to other trials on cerebral protection during TAVR, thus warranting a larger study. (European Study Evaluating the Emblok Embolic Protection System During TAVR.</p>
Clopidogrel Resistance and Ticagrelor Replacement in Dual Antiplatelet Therapy for Carotid Artery Stenting
<p>Mazzaccaro D, Giannetta M, Ranucci M, Righini P, Di Dedda U, Baryshnikova E, Milani V, Nano G. Clopidogrel Resistance and Ticagrelor Replacement in Dual Antiplatelet Therapy for Carotid Artery Stenting. Ann Vasc Surg. 2022 Oct 19:S0890-5096(22)00640-9. doi: 10.1016/j.avsg.2022.09.063. Epub ahead of print. PMID: 36270550.</p> <p>Abstract</p> <p><strong>Backgrounds: </strong>Resistance to the pharmacological effect of clopidogrel in patients undergoing dual antiplatelet therapy for carotid stenting may increase the risk of periprocedural neurological events. The purpose of the study was to describe the phenomenon of clopidogrel resistance in a series of patients undergoing carotid stenting.</p> <p><strong>Methods: </strong>Data of patients who consecutively underwent carotid stenting from November 2016 to December 2020 for a significant stenosis and who underwent a dual antiplatelet therapy using acetyl-salicylic acid and clopidogrel were prospectively collected. Patients who were already taking a different thienopyridine were excluded. The effectiveness of antiplatelet drugs was assessed by the impedance aggregometry test. Primary endpoint was to evaluate the incidence of clopidogrel resistance and the effectiveness of ticagrelor as alternative therapy. P values < 0.05 were considered statistically significant.</p> <p><strong>Results: </strong>Two-hundred patients (80 females, 40%) underwent stenting for carotid stenosis (94% asymptomatic). The phenomenon of clopidogrel resistance was observed in 38 patients (19%), in whom clopidogrel was replaced by ticagrelor (90 mg/bis in die) with 100% effectiveness at aggregometry test. Platelet counts was associated to clopidogrel resistance (P = 0.001). There was no stent thrombosis at 30 days, neither major hemorrhagic events; a total of 12/200 major adverse cardiovascular events occurred (6%), including 1 in the group of patients who took ticagrelor and 11 in group of patients under clopidogrel (2.6% versus 6.7%, P = 0.55).</p> <p><strong>Conclusions: </strong>Clopidogrel was ineffective in 19% of patients undergoing carotid stenting. Platelet count seemed to affect this phenomenon. In these patients, clopidogrel was effectively replaced by ticagrelor.</p>
Karyotype analysis of S. cerevisiae chromosome replacement lines
GEO Series GSE12785. Saccharomyces bayanus; Saccharomyces cerevisiae. 48 samples. Type: Genome variation profiling by genome tiling array.
WFUBMC Primate Center X-96-23: Cynomolgus macaque response to hormone replacement therapy
GEO Series GSE27228. Macaca fascicularis; Macaca mulatta. 16 samples. Type: Expression profiling by array.
REPLACED by GSE232887
GEO Series GSE160127. Mus musculus. 0 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
DELETED - Replaced by GSE280037
GEO Series GSE263217. . 0 samples. Type: Other.
REPLACED: EOS-DATA-2016-01: Monte Carlo Pseudo Events for the decays Bbar -> P mu X_nubar, P = D,pi
<p>This dataset has been replaced after an error in the original analytical calculation has been uncovered.</p> <p>This archive EOS-DATA-2016-01 contains pseudo events of the decays</p> <p> Bbar -> P mu X_nubar</p> <p>where X_nubar is either nubar or (nubar nu nubar), and P = D or pi. The archive<br /> complements the publication EOS-2016-01. The events are stored as binary files<br /> in the HDF5 format.</p>
Dataset related to the article "Looking back to look forward: what to expect in a REDO surgery for a bioprosthesis replacement"
<p>This record contains raw data related to the article “Looking back to look forward: what to expect in a REDO surgery for a bioprosthesis replacement”</p> <p>REDO surgeries are becoming more common because an increased rate of bioprosthesis implantation. We performed Retrospective study on patients who underwent replacement of aortic and/or mitral bioprosthesis between 2005 and 2018 to evaluate intra-hospital mortality and morbidity. Univariate analysis is performed on the propensity score variables to determine predictors of mortality. A total of 180 patients were enrolled in the study: Group A (replacement of aortic bioprosthesis) with 136 patients (75.56%) and group B (replacement of mitral bioprosthesis ± aortic bioprosthesis) with 44 patients (24.44%). NYHA class≥3 and female sex were significantly more common in group B. Cardiopulmonary-bypass time and aortic cross-clamping time in group A and group B were, respectively, 154.95±74.35 and 190.25±77.44 (p=0.0005) and 115.99±53.54 and 144.91±52.53 (p=0.0004). Overall mortality was 8.89%. At propensity score adjustment, Group B was confirmed to have an increased risk of death (OR 3.32 CI 95% 1.02 – 10.88 p < 0.0001), gastro-intestinal complications (OR 7.784 CI 95% 1.005 – 60.282 p< 0.0002) and pulmonary complications ( OR 2.381 CI 95% 1.038 – 5.46 p < 0.0001). At the univariate analysis, endocarditis, cardiopulmonary-bypass and aortic cross clamping time, NYHA class≥3, urgency setting were significantly associated to death. Intra-hospital outcomes are acceptable regarding mortality and complications. Patients who need REDO surgery on mitral bioprosthesis have an increased risk of post operative pulmonary and gastro-intestinal complications and mortality. Therefore the choice of mitral bioprosthesis at time of first surgery should be carefully evaluated.</p>
Post-operative and mid-term hemodynamic changes after replacement of the ascending aorta
<p>To evaluate aortic distensibility and pulse waveform patterns associated with the ascending aortic aneurysm, and to analyze the postoperative and mid-term hemodynamic changes induced by prosthetic replacement of the ascending aorta. Central blood pressure waves were recorded at the carotid artery level by means of a validated transcutaneous arterial tonometer in 30 patients undergoing prosthetic replacement of ascending aortic aneurysm and in 30 control patients. Measurements were obtained the day before surgery and 5 to 7 days and 16 to 20 months after surgery. The ascending aortic aneurysm was associated with a less steep slope of early systolic phase of the pressure curve (pulsus tardus) compared with a control group (0.54 ! 0.18 mm Hg/ms vs 0.69 ! 0.26 mm Hg/ms; P .011). Replacing the ascending aorta with a noncompliant vascular prosthesis steepened the pulse pressure slope during the early systolic phase in the postoperative period (0.77 ! .29 mm Hg/ms), providing values comparable with those of the control group in the mid-term (0.67 ! .20 mm Hg/ms). No change in aortic stiffness was found either postoperatively or in the mid-term after ascending aorta surgical replacement (carotid-femoral pulse wave velocity: preoperative, 9.0 ! 2.6 m/s; postoperative, 9.0 ! 2.9 m/s; mid-term postoperative, 9.3 ! 2.8 m/s). This study does not con!rm the assumption that substitution of the viscoelastic ascending aorta with a rigid prosthesis can cause serious hemodynamic alterations downstream, because we did not observe a worsening of global aortic distensibility after insertion of a rigid prosthetic aorta. The ascending aortic aneurysm is associated with a pulsus tardus.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.